MDx Impact Grants

The MDx Impact Grants aim to unlock the potential of PCR to democratise access to accurate diagnostic tests that improve patient outcomes.

We invite research groups to work with us and our partner Seegene to develop tests that address unmet clinical needs. The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants of up to 600,000 USD to perform clinical studies. 

Each research group is permitted to submit only one application focused on the designated project. We welcome applications from eligible research groups from around the world.  

2025 Scope: Urinary Tract Infection (UTI) Drug Resistance (DR)

This year, the MDx Impact Grants focus on Urinary Tract Infection (UTI) Drug Resistance (DR) genes that correspond to clinically important antibiotic resistance genes, such as, CTX-M, KPC, NDM and vanA. Your proposal must include a minimum of nine (9) and up to a maximum of eighteen (18) target genes excluding internal controls.

Before you apply

We invite applications from eligible research groups all around the world. Research groups are required to have access to BSL-2 (Biosafety level 2) facilities, experience in PCR, access to relevant clinical specimens and eligibility to conduct clinical studies for in vitro diagnostic (IVD) validation in accordance with applicable regulatory requirements. At the time of submission, all applicants are required to state that they have reviewed and agree to the Terms and Conditions of the programme.

Key dates

2 September 2025

Open date

20 November 2025

Close date (23:59 GMT)

November 2025 to August 2026

Application assessment

Mid-March 2026

Shortlist announcement

Mid-August 2026

Successful applicants notified